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Abstract
This manuscript contains the conclusion of the consensus meeting of the 
Brazilian Sleep Association with Brazilian sleep specialists on the treatment of 
narcolepsy based on the review of medical literature from 1980 to 2010. The 
manuscript objectives were to reinforce the use of agents evaluated in randomized 
placebo-controlled trials and to issue consensus opinions on the use of other 
available medications as well as to inform about safety and adverse effects of 
these medications. Management of narcolepsy relies on several classes of drugs, 
namely, stimulants for excessive sleepiness, antidepressants for cataplexy and 
hypnotics for disturbed nocturnal sleep. Behavioral measures are likewise valuable 
and universally recommended. All therapeutic trials were analyzed according 
to their class of evidence. Recommendations concerning the treatment of each 
single symptom of narcolepsy as well as general recommendations were made. 
Modafinil is the first-line pharmacological treatment of excessive sleepiness. 
Second-line choices for the treatment of excessive sleepiness are slow-release 
metylphenidate followed by mazindol.  The first-line treatments of cataplexy 
are the antidepressants, reboxetine, clomipramine, venlafaxine, desvenlafaxine 
or high doses of selective serotonin reuptake inibitors antidepressants. As for 
disturbed nocturnal sleep the best option is still hypnotics. Antidepressants 
and hypnotics are used to treat hypnagogic hallucinations and sleep paralysis.
Descriptors: Antidepressants; Cataplexy; Stimulants; Narcolepsy; Excessive 
sleepiness
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Resumo
Este artigo relata as conclusões da reunião de consenso da Associação Brasileira de Sono 
com médicos especialistas brasileiros sobre o tratamento da narcolepsia, baseado na 
revisão dos artigos sobre narcolepsia publicados entre 1980 e 2010. Os objetivos do 
consenso são valorizar o uso de agentes avaliados em estudos randomizados placebo-
controlados, emitir recomendações de consenso para o uso de outras medicações e 
informar pontos importantes a respeito da segurança e efeitos adversos das medicações. 
O tratamento da narcolepsia é baseado em diversas classes de agentes, estimulantes 
para sonolência excessiva, agentes antidepressivos para cataplexia e hipnóticos para 
sono noturno fragmentado. Medidas comportamentais são igualmente importantes 
e recomendadas universalmente. Todos os ensaios clínicos terapêuticos foram 
classificados de acordo com o nível de qualidade da evidência. Recomendações 
terapêuticas individualizadas para cada tipo de sintoma e recomendações gerais 
foram formuladas pelos autores. Modafinila é indicada como a primeira escolha para 
o tratamento da sonolência diurna. Agentes de segunda escolha para o tratamento 
da sonolência excessiva são metilfenidato de liberação lenta seguido pelo mazindol. 
Reboxetina, clomipramina, venlafaxina, desvenlafaxina e os inibidores seletivos de 
recaptação de serotonina em doses altas são a primeira escolha para o tratamento da 
cataplexia. Hipnóticos são utilizados para o tratamento do sono noturno fragmentado. 
Antidepressivos e hipnóticos são igualmente utilizados para o tratamento das 
alucinações hipnagógicas e paralisia do sono.
Descritores: Antidepressivos; Cataplexia; Estimulantes; Narcolepsia; Sonolência 
excessiva 
Aloé F et al.
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Introduction
The current paper presents the conclusions drawn by the sleep 
specialists attending the consensus meeting of the Brazilian Sleep 
Association in 2010. The conclusions reached for the treatment of 
narcolepsy are based on a review of the medical literature investigating 
narcolepsy published between 1980 and 2010. 
The objectives of the consensus meeting were to assess the use of 
agents that have been tested in randomized placebo-controlled studies 
for the treatment of narcolepsy, to issue consensus recommendations 
for the use of alternative medications, and to provide information 
about important safety and adverse effects caused by such medications. 
Goals of the treatment of narcoleptic symptoms
Treatment goals include the control of daytime and nighttime 
symptoms as well as psychosocial adaptation. Central nervous system 
(CNS) stimulating agents, antidepressants, hypnotic agents, sleep 
hygiene measures, and psychosocial and psychotherapy support are 
all ubiquitously employed in the treatment of narcolepsy.1  
The treatment categories presented herein are based on the 
evaluation of the scientific evidence provided by clinical studies.2 The 
classification of the types of clinical studies is shown in Table 1 and 
their findings are summarized in Table 2. 
This treatment categorization was based on a literature search 
(Medline and Cochrane Controlled Trials Register) and on a systematic 
review of all relevant articles about narcolepsy treatments that were 
published between 1980 and 2010. 
The guidelines are complemented by specific levels of 
recommendation, namely, “standard”, “guideline”, “optional”, or 
“consensus”. These recommendation levels have been incorporated 
into this document.2-4 The three first recommendation levels represent 
articles with levels from I to III (Table 1). 
Recommendations resulting from the consensus 
meeting
Whenever empirical data were limited or non-conclusive, the 
specialists would cast their vote for the most recommended treatment. 
When only class IV and V studies were available but not class I, II, 
and III, the recommendation was decided when the majority of the 
members of this consensus (> 80%) voted in agreement. In this way, 
the agreed recommendations took into account the scientific expertise 
and personal experience of each member of the consensus.5
Behavioral treatment 
1. Adequate sleep hygiene 
Recommendation level D with degrees of evidence IV and V. 
Sleep hygiene measures increase the efficacy of the pharmacological 
treatment for excessive sleepiness6-9 and consist of:
• maintenance of regular sleep and wake schedules;
• avoidance of alcohol and sedatives; 
• avoidance of excess and/or abstinence of chocolate and caffeinated 
beverages;
• avoidance of sleep deprivation; 
• tobacco abstinence; and 
• avoidance of meals rich in carbohydrates. 
2. Naps
Recommendation level B with degree of evidence III. 
Scheduled morning and afternoon naps improve the level of alertness 
and allow for the reduction of stimulant dosage.10-12 
3. Social measures 
Recommendation level D with degree of evidence V. 
Adaptation of work schedules to accommodate naps.6-8
4. Psychological support 
Recommendation level D without support from publications. 
Psychological support for the adaptation to and acceptance of 
sleepiness and cataplexy symptoms.6-8
5. Pharmacological treatment 
Recommendation level A with degree of evidence I. 
6. Excessive Sleepiness (ES) treatment 
1) CNS stimulants (Table 3). CNS stimulants reduce the intensity 
of sleepiness to 65 - 90% of the pre-treatment level.1,4,7,8,11,13
Modafinil
Modafinil is currently classified as an atypical stimulant due to its 
chemical structure, its pharmacodynamic mechanisms of action, and 
its distinct neurobehavioral effects. 
The primary cellular mechanisms of modafinil in CNS 
neurotransmission are: 
1) Blockade of dopamine transporter (DAT) reuptake protein with 
low-affinity, which in turn enhances D1-D2 meso-cortico-limbic 
dopaminergic neurotransmission.14-18
2) Intensification of electrical synchronization of GABAergic gap-
junctions of GABAergic cells within the cholinergic pedunculopontine 
nucleus. Such electrical synchronization leads to cholinergic and 
glutamatergic excitatory activity within the brain stem nuclei and 
cerebral cortex.19-28
3) hypocretin-dependent increase of histaminergic neurotransmission 
in the posterior tuberomammillary hypothalamic nuclei.14,29
1. Effects of modafinil on narcolepsy related to exces-
sive sleepiness 
Recommendation level A with degree of evidence I. 
Two multicentric studies (US Modafinil in Narcolepsy Multicenter 
Study Group), which included 550 narcoleptic patients followed-
up for 9 consecutive weeks, demonstrated that doses of 200 mg of 
modafinil once a day, or 400 mg divided in two doses, improved 
daytime sleepiness up to 71% from baseline, as measured by the 
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Epworth Sleepiness Scale (a decrease from 18 to 12 points). The same 
studies also reported an increase of 40% in sleep latency recorded in 
the Multiple Sleep Latency Test (MSLT) and a 54% increase in sleep 
latency recorded in the Maintenance of Wakefulness Test (MWT).29,30 
A non-significant reduction of cataplexy attacks was also observed.29,30 
Additional randomized studies in which patients were followed-up for 
40 weeks, and open studies wherein patients were followed for 136 
weeks, produced encouraging results in the control of somnolence.1,31-33 
2. Doses of modafinil for the treatment of sleepiness 
in narcolepsy 
Pharmacologic treatment for narcolepsy consists of 100mg of 
modafinil in the morning, which is increased by 50 to 100 mg every 
five days. The safest dose of modafinil is 200mg in the morning, 
which can be increased over two weeks up to 200, 300, or 400mg 
per day in the morning if residual symptoms of sleepiness are still 
present.1,31-34 The regimen in which the doses are divided into 200mg 
in the morning and 200mg in the afternoon is safer when compared 
to a single 400mg morning dose because it has been shown to be more 
efficient and to have fewer adverse effects, and it also prevents the 
resurgence of sleepiness towards the end of the day. The maximum safe 
dose of modafinil is 600mg per day.1,31-34 Subpopulations of Caucasian 
narcoleptic women respond to lower doses of modafinil due to a sexual 
dimorphism of the gene that modulates catechol-O-methyl transferase 
(COMT), which metabolizes dopamine within the synaptic cleft.35
3. Clinical pharmacokinetics of modafinil 
Modafinil is well absorbed orally, and the onset of its action occurs 
in approximately two hours after oral administration. The ingestion of 
food delays intestinal absorption of the drug by about one hour. The 
half-life of modafinil is between 9 and 14 hours, and the drug reaches 
a steady-state after 2 to 4 days of use.36,37 Ninety percent of modafinil 
metabolization occurs with cytochrome CYP-450 yielding no CNS 
active metabolites.36-38 The rate of renal excretion is reduced in up to 
20% in patients over 65 years of age. The dose of modafinil must be 
reduced by half in cases of hepatic and renal failure.38 
4. Drug interactions with modafinil 
Modafinil reversibly inhibits the CYP2C19 isoenzyme of 
cytochrome CYP-450 and prolongs the half-life of calcium channel 
antagonists, as it does for statins, omeprazole, clomipramine, clozapine, 
selective serotonin reuptake inhibitors (SSRIs), buspirone, midazolam, 
diazepam, propranolol, phenytoin, and warfarin, the last of which 
requires blood testing to control prothrombin time.38 
Modafinil induces the CYP3A4 isoenzymes responsible for the 
metabolism of ethinyl estradiol, which is an oral contraceptive agent, 
thus resulting in the reduction of the plasmatic concentration of 
estradiol for up to a month after the patient ceases taking modafinil.38,39 
An additional dose of at least 50µg of estradiol during the use of 
modafinil is clinically recommended. Also, two additional months of 
at least 50µg of estradiol after the patient has ceased taking modafinil 
is also a recommendation. 
The co-administration of isoenzyme P450 inducers, such as 
carbamazepine, phenobarbital, and rifampcin, or inhibitors of the 
isoenzyme P450 such as ketoconazole, can affect the plasmatic 
concentration of modafinil.
Therapeutic doses of modafinil can be safely used along with all 
classes of monoamine oxidase inhibitors (MAOI). Studies with healthy 
volunteers demonstrated that there was no interaction between dextro-
amphetamine, methylphenidate, and amphetamines and modafinil 
when acutely co-administered. Also, in cocaine-addicted individuals, 
there was no interaction between cocaine and modafinil, with no 
further risks of autonomic effects.38,39 There are no studies evaluating 
the interaction between modafinil and alcohol. 
5. Substitution of other stimulants for modafinil 
The substitution of methylphenidate or amphetamine for 
modafinil must be done using meticulous clinical criteria, its use being 
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supported by the rationale that sympathomimetic drugs are less safe 
than modafinil. Switching from sympathomimetics to modafinil is 
accomplished with a slow reduction of the sympathomimetic stimulant 
and the gradual introduction of modafinil. The introduction of a 
specific anti-cataplectic agent or a dose increase of the anti-cataplectic 
already in use should be put into practice to avoid cataplexy episodes 
during the switching process, as modafinil is not particularly effective 
against cataplexy.40-42
6. Adverse and side effects of modafinil amongst the 
narcoleptic population 
Side effects of modafinil in doses of up to 600mg/day occur in less 
than 5% of users. Headaches are most frequent (13%) and are limited 
to the first three weeks of treatment. Headaches are more commonly 
observed in association with a rapid increase in the modafinil dosage. 
This side effect may well be avoided by increasing the dose slowly. 
Nervousness (8%), diarrhea, nausea (5%), rhinitis symptoms, 
hypertension, appetite reduction, and weight reduction were additional 
side effects reported.43 
Modafinil (up to 600mg/day) does not cause central and autonomic 
nervous system side effects in the narcoleptic population, such as psycho-
motor agitation, insomnia, anxiety, tolerance, and/or dependence.29,30,32 
There are no accounts of suicide attempts with modafinil.
7. Allergic reactions related to modafinil 
Allergic reactions as angioedema and Stevens-Johnson syndrome 
were reported with the use of modafinil. However, such cases are quite 
uncommon and their occurrence is confounded by the prevalence of 
both conditions in the general population. Should an allergic reaction 
emerge in association with modafinil use, the clinical recommendation 
is to stop the treatment with modafinil promptly. Systemic 
inflammatory reactions in multiple organs, such as myocarditis, 
hepatitis, eosinophilia, leucopenia, thrombocytopenia, itching, and 
asthenia have been reported. There are no predictive clinical markers 
for these adverse effects.38 
8. Effects of modafinil in the hypothalamic- 
pituitary-adrenal axis 
Modafinil does not cause neuroendocrine alterations, such as 
activation of the hypophysis-pituitary axis. There is no increase in 
adrenocorticotropic hormones, cortisol, or changes in prolactin or 
growth hormone secretion.29,30,32,38,39
9. Metabolic changes caused by modafinil
Mild elevation of gamma-GT and alkaline phosphatase hepatic 
enzymes can occur.29,30,32,38,39
10. Modafinil contraindications7,32,38,39 
• Age under 16; 
• pregnancy;
• breast-feeding;
• uncontrolled arterial hypertension;
• hypertrophy of the left ventricle; 
• ischemic ECG alterations; 
• cardiac arrhythmias;
• typical or unstable angina; 
• recent acute myocardial infarction; and
• mitral valve prolapse. 
11. Modafinil abuse potential in narcoleptic 
populations 
Evidence from preclinical animal studies and clinical human 
studies suggests that modafinil does not present risks for abuse and 
dependence when used in therapeutic doses in clinical populations 
not prone to abuse. This finding is contrary to those related to other 
sympathomimetic stimulants such as amphetamines, methylphenidate, 
and caffeine.38,44-47
Modafinil (up to 600mg/day) holds a low potential for abuse not 
only in narcoleptic populations but also in individuals with obstructive 
sleep apnea syndrome and shift workers.29,30,32,43-45 
Modafinil is currently classified as a Schedule IV drug by the 
Food and Drug Administration (which indicates a low potential 
for abuse and a limited potential for physical and psychological 
dependence).48 In Brazil, modafinil is classified by the Sanitary 
Vigilance Agency (ANVISA) as an A3 drug (yellow prescription 
form). 
12. Symptoms of modafinil withdrawal in 
narcoleptic populations 
There are no accounts of abstinence or withdrawal syndrome 
due to the sudden discontinuation of modafinil used in therapeutic 
doses.38,39,45 Rebound excessive sleepiness can occur after sudden 
discontinuation of 400mg/day doses.29,32 
13. Armodafinil
Armodafinil is the R-enantiomer of modafinil, and it has a half-life 
of approximately 15 hours.49 Armodafinil is not available in Brazil.
Amphetamine-like stimulants 
1. Amphetamine
In usual clinical therapeutic doses, amphetamines are potent 
sympathomimetic drugs that enhance dopaminergic and noradrenergic 
neurotransmission in the nervous system.14,16,50
2. Cellular mechanisms of amphetamine action 
Amphetamines block the dopamine transporter (DAT) and 
noradrenaline (NAT) reuptake proteins with high affinity. This leads 
to the following: 
1) increased activation of D1-D2 meso-cortico-limbic receptors;14,16,50
2) increased noradrenergic neurotransmission within the locus 
coeruleus;14,16,50
3) increased pre-synaptic dopaminergic and noradrenergic release 
into the synaptic cleft; and 
4) monoamine oxidase (MAO) inhibition with supra-therapeutic 
doses of amphetamine.14,16,50
3. Types of amphetamines
Dextroamphetamine and dextromethamphetamine are more potent 
than the other known isomers.14,16,50
Dextromethamphetamine is more lipophilic and acts more rapidly 
and efficiently with less peripheral effects, but has a higher potential 
for abuse and dependence that renders it unsafe for clinical use.14,16,50
4. Methylphenidate and amphetamines 
Recommendation level B with degree of evidence III. 
The mechanism of action of methylphenidate is similar to that of 
amphetamines.14,16,50
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The onset of the action of methylphenidate occurs one hour after the 
oral administration, and its half-life ranges from three to four hours, 
requiring the use of more than one dose per day.14,16,50
Eighty percent of methylphenidate is metabolized by the 
liver producing an inactive metabolite.14,16,50 Amphetamines 
and methylphenidate have been found to improve narcolepsy 
baseline sleepiness up to 65-85%.51,52 The maximum daily dose of 
methylphenidate recommended by the American Academy of Sleep 
Medicine and by the European Federation of Neurological Societies 
is 100mg per day.1,8,9
5. Stimulant contraindications
Amphetamines and methylphenidate are not recommended for 
patients with glaucoma, anxiety disorders, tics, or a history of Giles de 
la Tourette’s syndrome.14,51,52 Also, amphetamines and methylphenidate 
are contraindicated for patients with arterial hypertension, thoracic 
pain, cardiac arrhythmias, mitral prolapse, ventricular hypertrophy, 
angina, and acute myocardial infarction.49,50,52
Patients with depression, psychosis, epilepsy, and cardiovascular 
comorbidity must be carefully evaluated when the use of 
methylphenidate is under consideration.14,51,52
6. Adverse effects of stimulants 
Psychiatric side-effects are uncommon in the narcoleptic population, 
but systemic arterial hypertension can occur with use of therapeutic 
doses.14,51-54
7. Abuse and tolerance 
Sympathomimetic stimulants are classified as Schedule II in the 
Controlled Substance Act due to their high potential for abuse and 
tolerance.9 Abuse and dependence are uncommon and occur in 1-3% 
of narcoleptic patients.14,50,55,56 
Mazindol 
Recommendation level A with degree of evidence I. 
The mechanism of action of mazindol is similar to that of 
amphetamines.6 
The dose peak occurs in one to two hours, and the drug has a 10-hour-
long half-life. Prescribed doses range from 1 to 4mg/day, starting with 
low doses.1,8,9 Mazindol reduces ES in 53% to 60% of patients and it 
also has anticataplectic effects.14,50,55-59 Mazindol is metabolized in the 
liver into inactive compounds with kidney and fecal excretion. 
Selegiline 
Recommendation level C with degree of evidence IV. 
Selegiline is a selective, reversible, potent inhibitor of MAO-B 
enzyme when used in doses of 5 to 20mg/day.14,16,50 However, 
in doses over 20mg, selegiline fails to retain its properties as a 
selective MAO-B inhibitor, thus requiring a tyramine-poor diet. 
Selegiline is metabolized in the liver into amphetamine and 
methamphetamine contributing to the reduction of daytime 
sleepiness.14,50
Selegiline is usually better tolerated than amphetamine-like drugs 
and possesses a clinically relevant anti-cataplectic effect. However, 
its use is limited by its sympathomimetic effects and its interactions 
with other drugs.60,61 
Pemoline 
Pemoline is no longer available due to its hepatotoxic effects, which, 
although rare, are potentially lethal.62,63 It is not available in Brazil.
Caffeine
Recommendation level C without support from publications. 
High doses (> 450mg/day) of caffeine improve alertness but can 
produce tremors, irritability, gastrointestinal symptoms, and excessive 
dieresis.14,50,64
Treatment of refractory excessive sleepiness or exces-
sive sleepiness relapse 
1. Combination of stimulant agents
Recommendation level C with degree of evidence IV. 
Approximately 65% to 85% of patients respond satisfactorily 
to stimulants.53,55 In the refractory cases, modafinil can be used 
(400mg to 600mg/day, 400mg in the morning plus 200mg after 
lunch). Alternatively, in addition to modafinil doses of 200 to 
300mg/day, 5 to 10mg of rapid onset-of-action methylphenidate 
can be added under judicious clinical care.1 There are no 
studies evaluating the safety of the association of different 
types of stimulants in the treatment of narcoleptic patients 
(methylphenidate and modafinil, amphetamine and modafinil, 
and amphetamine and methylphenidate). 
2. Agents chosen for the treatment of ES 
Recommendation level A with degree of evidence I. 
The first-choice treatment for ES is modafinil 200-400mg/day,1,6-
9,14,29-33,50 since doses over 600mg/day are not considered safe. The 
second choice is slow-release methylphenidate in doses up to 120mg/
day1,6-9,14,29-33,50 (Table 5). Methylphenidate has been found to be safer 
than mazindol and amphetamines.6-9,14,29-33,50
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Cataplexy treatment
Sympathomimetic stimulants reduce the frequency and intensity 
of cataplexy attacks.1,6-9 Modafinil, however, has not been found to 
improve cataplexy.29-33 The recommended treatment for cataplexy 
is based on antidepressants.65
Antidepressants
1. Tricyclic Antidepressants (TCA) 
Recommendation level B with degree of evidence III for 
cataplexy. 
Recommendation level C with degree of evidence IV for sleep 
paralysis and hypnagogic hallucinations. 
TCA are effective in the treatment of cataplexy. However, their 
side effects may pose a limitation to their use.1,6-9,64,65 TCA used in 
the treatment of cataplexy include nortriptyline (25-200mg/day), 
clomipramine (25-150mg/day), and imipramine (10-100mg/
day).65,66 
2. SSRI antidepressants 
Recommendation level B with degree of evidence III for 
cataplexy. 
Recommendation level C with degree of evidence III for sleep 
paralysis and hypnagogic hallucinations. 
SSRIs such as fluoxetine (20-80mg/day),67 paroxetine (20-60mg/
day),68 sertraline (50-150mg/day),65 and citalopram (20mg)69 are 
less efficient than TCA and noradrenaline selective reuptake 
inhibitors (NSRIs) in the treatment of cataplexy. Equivalent or 
even higher doses of SSRIs than those used in the treatment of 
depression are required to control cataplexy.65,66 
3. Serotonin and Noradrenaline Reuptake Inhibitor 
(SNRI) antidepressants
Recommendation level B with degree of evidence III for 
cataplexy. 
Recommendation level C with degree of evidence IV for sleep 
paralysis and hypnagogic hallucinations. 
1) Venlafaxine 
Venlafaxine (75-225mg/day) is clinically effective in the 
treatment of cataplexy, hypnagogic hallucinations, and sleep 
paralysis.65,66,70 The noradrenergic effect of venlafaxine can increase 
the autonomic effect of sympathomimetic drugs upon the systemic 
arterial pressure and the heart rate of the patient.14,50,54 Thus, the 
arterial blood pressure must be monitored when venlafaxine is 
combined with other stimulants. 
2) Desvenlafaxine
Desvenlafaxine is a hepatic metabolic sub-product of 
venlafaxine. Desvenlafaxine presents a milder array of side-
effects in comparison to venlafaxine. It is therefore a suitable 
alternative to venlafaxine and other antidepressants used for the 
treatment of cataplexy. However, there are no studies on the 
effects of desvenlafaxine in narcolepsy. Arterial blood pressure 
must be monitored when desvenlafaxine is combined with other 
stimulants. 
4. NSRI antidepressants 
Reboxetine
Recommendation level B with degree of evidence III for 
cataplexy. 
Recommendation level C with degree of evidence IV for sleep 
paralysis and hypnagogic hallucinations. 
One study involving 12 patients treated with up to 10mg/day 
of reboxetine demonstrated a 48% reduction in the Epworth 
Sleepiness Scale, a 54% reduction in the sleep latency on the 
MSLT, and a significant reduction in cataplexy attacks.71 
5. Conclusions concerning the treatment of 
cataplexy with antidepressants 
The most effective antidepressants for the treatment of cataplexy 
are reboxetine, venlafaxine, clomipramine, nortriptyline, and 
combinations of these antidepressants (Table 6).1,6-9,24,50,65,66 
Tolerance to the anticataplectic effects has been described, and 
increments of the dose or medication change may be necessary 
in these cases. 
6. Other antidepressant agents
Irreversible MAO-A and -B inhibitor agents can be used in the 
treatment of cataplexy;14,50 however, there is no scientific evidence 
on the efficiency and safety of this drug class in the treatment of 
cataplexy.14,50
Other agents used to treat cataplexy
Selegiline and mazindol can be used in cases of cataplexy 
resistant to the agents mentioned above.6,8,50,60,61,65,72 The use 
of selegiline is limited by its potential of interaction with other 
drugs and with tyramine, which could cause severe hypertensive 
crises.50,72
Gamma-hydroxybutyrate (GHB) 
GHB belongs to a distinct drug category, partly due to its 
therapeutic effects in cataplexy, in sleepiness, and in fragmented 
nocturnal sleep.73-77 GHB is not available in Brazil. 
Anticataplectic agent withdrawal, rebound, and 
status cataplecticus
The sudden withdrawal of anticataplectic antidepressants 
can cause cataplexy rebound or status cataplecticus, which is 
characterized by an increase in the length, frequency, and intensity 
of the cataplectic episodes.7,65 
The intensity of the status cataplecticus as well as the intensity of 
the rebound phenomenon are directly proportional to the clinical 
pharmacological strength of the anticataplectic agent, as well as 
to its sudden discontinuation. 
Contraindicated drugs for the narcoleptic popula-
tion with cataplexy
Anti-hypertensive agents that reduce the central adrenergic 
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neurotransmission, such as prazosin and clonidine, worsen 
cataplexy seizures.50 
Medication interactions during the treatment of 
narcolepsy 
The combination of multiple agents for the treatment of 
narcolepsy is not uncommon along the treatment of this condition. 
No reports exist of significant and unsafe clinical pharmacokinetic 
interactions between methylphenidate and modafinil or between 
dextroamphetamine and modafinil.14,50,55,78
Conversely, there are potential significant interactions 
between tricyclic antidepressants, SSRIs, selegiline, modafinil, 
amphetamines, and prazosin. These interactions are not generally 
clinically important, but the attending physician should be aware 
of them (Table 7).14,50,54,78,79
Sleep paralysis and hypnagogic hallucinations  
Recommendation level C without support from publications.
The American Academy of Sleep Medicine and the European 
Federation of Neurological Societies list the antidepressant 
agents for the treatment of sleep paralysis and hypnagogic 
hallucinations.1,6-9 
Aside from these recommendations, hypnotic agents that 
consolidate fragmented sleep, such as zolpidem, zopiclone, 
benzodiazepines, and clonidine can be used.1,6-9,14 
Nocturnal fragmented sleep treatment 
Recommendation level D with degree of evidence IV. 
Zolpidem and triazolam can be used to consolidate nocturnal 
sleep.14,80 
Treatment of REM sleep behavior disorder and 
narcolepsy
Recommendation level D with degree of evidence IV. 
Clonazepam is the first-choice treatment for REM sleep 
behavior disorder, but about 10% of the cases do not respond to 
the drug.81 Treatment alternatives are melatonin, agomelatine, 
ramelteon, and pramipexole. Melatonin in doses between 3 and 
13mg was shown to be effective in 57% of the cases. 
Treatment of narcolepsy during pregnancy and 
lactation
Methylphenidate and modafinil are class C category agents for 
teratogenicity. 
There are no studies on the use of stimulants and anticataplectic 
agents during pregnancy and lactation in narcoleptic patients.14,82 
The only classes of agents in categories below C for teratogenicity 
are pemoline (which has been discontinued since 2005 due to 
hepatotoxicity) and GHB (which is class B but not available 
in Brazil). A safer alternative is to discontinue the use of the 
medication.14,82 Gradual discontinuation is recommended to avoid 
the recurrence of cataplectic seizures. 
When risks related to the symptoms are higher than the 
teratogenic risks, such as cataplexy accompanied by frequent falls 
or accidents due to sleepiness, fluoxetine and/or tricyclics are the 
recommended options. In these cases, special attention must be 
given to changes in arterial pressure caused by stimulants during 
pregnancy.14,82 
Cesarean sections are also recommended due to the risk of status 
cataplecticus during delivery. There are no studies on the safety of 
stimulants during lactation. It is not known whether modafinil 
is excreted in the mother’s milk. 
Compliance in the treatment of narcolepsy 
About 50% of patients with narcolepsy do not comply 
completely with the treatment and either reduce the dose of the 
drug or discontinue the medication altogether.55,56,83 There are no 
reports of clinical risk factors for low compliance rates. A suspicion 
of non-compliance should always be considered in cases in which 
the patient is resistant to the treatment. 
Conclusion
The individual therapeutic recommendations for each symptom 
as well as the general recommendations set forth herein were 
formulated by the authors. It was agreed among the sleep specialists 
attending the 2010 consensus meeting of the Brazilian Sleep 
Association of 2010 that modafinil is the first choice for the 
treatment of daytime sleepiness. Second-choice agents for the 
treatment of ES are slow-release methylphenidate and mazindol. 
Reboxetine, clomipramine, venlafaxine, desvenlafaxine, and high 
doses of SSRIs were agreed as being the first choice of treatment 
for cataplexy. Hypnotics, in turn, were recommended for the 
treatment of nocturnal fragmented sleep. Finally, antidepressants 
and hypnotics were recommended to be equally utilized in the 
treatment of hypnagogic hallucinations and sleep paralysis. 
This article attempted to objectively characterize the 
individualized treatment of narcolepsy in Brazil. The authors trust 
it will serve its purpose well, which is to offer a form of reference 
to sleep professionals throughout the country. 
Aloé F et al.
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